+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Adriamycin"

Ovarian Cancer Drugs Market Report 2025 - Product Thumbnail Image

Ovarian Cancer Drugs Market Report 2025

  • Report
  • March 2025
  • 175 Pages
  • Global
From
Doxorubicin Market Report 2025 - Product Thumbnail Image

Doxorubicin Market Report 2025

  • Report
  • February 2025
  • 200 Pages
  • Global
From
Diffuse Large B-Cell Lymphoma Therapeutics Market Report 2025 - Product Thumbnail Image

Diffuse Large B-Cell Lymphoma Therapeutics Market Report 2025

  • Report
  • February 2025
  • 200 Pages
  • Global
From
From
Doxorubicin Market Report and Forecast 2023-2031 - Product Thumbnail Image

Doxorubicin Market Report and Forecast 2023-2031

  • Report
  • May 2023
  • 140 Pages
  • Global
From
  • 6 Results (Page 1 of 1)
Loading Indicator

Adriamycin (doxorubicin) is a chemotherapy drug used to treat a variety of cancers, including lung cancer. It is a type of anthracycline antibiotic, derived from Streptomyces bacteria, and works by interfering with the growth of cancer cells. Adriamycin is administered intravenously and is often used in combination with other drugs to treat lung cancer. It is also used to treat other types of cancer, such as breast, ovarian, and bladder cancer. Adriamycin is a widely used drug in the treatment of lung cancer, and is often used in combination with other drugs to maximize its effectiveness. It is generally well tolerated, although it can cause side effects such as nausea, vomiting, hair loss, and fatigue. It is also associated with an increased risk of heart damage, so patients must be monitored closely for any signs of cardiac toxicity. Some companies in the Adriamycin market include Pfizer, Bristol-Myers Squibb, and Merck. Show Less Read more